While the use of lab animals is critical for scientific and medical advancements, it is equally important to address the ethical and scientific need for alternative methods. Developing and implementing alternatives, such as in vitro models, computer simulations, and advanced imaging techniques, can reduce reliance on animal testing, addressing ethical concerns and potentially offering more precise and human-relevant data.
The ethical imperative and scientific need for alternatives
Lab managers must navigate several competing priorities in the animals versus alternatives debate. Animal welfare concerns and increased transparency have intensified pressure to reduce lab animal use, leading to stricter ethical standards and greater emphasis on humane research practices enforced by regulatory bodies. This scrutiny, amplified by animal rights activism and high-profile campaigns, has pushed companies to improve their public image and adhere to Corporate Social Responsibility standards by reducing or eliminating animal testing in their R&D processes.
Get training in Biosafety and Biosecurity and earn CEUs.
One of over 25 IACET-accredited courses in the Academy.
Biosafety and Biosecurity course
In addition, studies have shown that animal models often lack human relevance, failing to accurately mimic human biology and disease mechanisms. This lack of predictive accuracy increases the failure rate of clinical trials, as effectiveness in animals does not always translate to humans. To better study complex diseases like Alzheimer's, improved models are needed to enhance reproducibility and reduce time and costs in R&D processes. Two technologies in particular are posed to offer more precise and relevant data than current models: advanced imaging technology and in silico models.
Advanced imaging techniques to reduce animal use
Reducing lab animal usage is a crucial step towards ultimately eliminating their use. A gradual transition ensures that alternative methods are validated and can reliably replace animal models without compromising scientific integrity or necessitating unnecessary animal sacrifice. This gradual transition can be achieved by utilizing imaging and perfusion systems, thereby limiting animal usage.
Functional Magnetic Resonance Imaging (fMRI)
Non-invasive imaging techniques like MRI utilize strong magnetic fields and radio waves to produce detailed internal structure images without invasive procedures. Functional MRI, or fMRI, measures brain activity by tracking changes in blood flow, making it valuable in neuroscience research. Contrast agents enhance MRI's accuracy in detecting and characterizing tumors by highlighting specific tissues. MRI's capability for longitudinal studies enables repeated imaging of subjects over time, facilitating research into disease progression and treatment outcomes. MRI has been successfully used to monitor tumor growth and treatment responses1 in cancer studies, assess heart function and structure2 for cardiovascular research, and track distribution and effectiveness3 of new drugs in animal models.
Reducing lab animal usage is a crucial step towards ultimately eliminating their use.
Positron Emission Tomography (PET)
PET is invaluable in research and development due to its capabilities in molecular imaging, providing insights into metabolic processes through the detection of radioactive tracers. This technology offers quantitative data on tracer concentration, enabling precise measurements of biological functions. When combined with Computed Tomography (CT) or MRI, PET delivers comprehensive imaging by integrating functional and structural information. Its ability to conduct dynamic studies allows for longitudinal tracking of changes, making PET particularly advantageous for studying drug development and disease progression over time. PET has recently been used to study tumor biology and therapy responses4, target neurotransmitter systems to study neurological disorders5, and track disease progression6 in animals while reducing the need for end-point studies.
Optical Imaging Techniques (OITs)
OITs encompass various techniques applicable to animal experiments. Bioluminescence imaging visualizes live animals' biological processes using light emitted from biological reactions like luciferase. Fluorescence imaging tags specific cells or molecules with fluorescent dyes or proteins, enabling their visualization and tracking within live animals. Multiphoton microscopy facilitates deep tissue imaging with minimal damage by using simultaneous absorption of multiple photons to excite fluorescent molecules within a specimen. This technique allows for detailed observation of live tissues and cellular interactions without requiring animal sacrifice. Optical coherence tomography produces high-resolution tissue images using light waves, similar to ultrasound, for precise structural analysis in biomedical studies.
Tissue sleeves and perfusion systems
Tissue slice techniques and perfusion systems offer valuable alternatives to live animal testing. Tissue slices are thin sections of organs or tissues maintained in controlled environments for ex vivo studies, preserving native architecture and cell-cell interactions. Precision-cut techniques ensure uniformity and viability, particularly in organs like the liver, brain, or lung, crucial for pharmacological and toxicological studies.
Perfusion systems circulate oxygenated blood or nutrient solutions through isolated organs or tissues, keeping them viable for extended periods. They mimic physiological conditions and are instrumental in studying organ functions and responses to drugs or toxins without the use of whole animals.
These methods provide viable alternatives to live animal testing by maintaining physiological relevance, preserving native tissue structures, and enabling high-resolution studies of cellular responses. They also substantially reduce animal numbers by allowing multiple experiments from a single organ or tissue sample. These techniques promote more humane research practices by minimizing the need for terminal experiments and offering precise models for drug development and disease research. However, despite their many advantages, these approaches still require the sacrifice of animals, making it necessary to also consider computer models as an essential component of modern research.
Computational models to replace animal usage
3D models and organoids7 are promising alternatives for replacing animal models, but some computer models and simulations promise an organism and cell-free experimental model.
Computational models play a pivotal role in R&D, offering powerful tools to simulate complex biological processes and predict outcomes. These models encompass a wide range of techniques, collectively known as in silico modeling, which utilize computational algorithms and data-driven simulations to mimic biological systems, drug interactions, and environmental responses.
In silico models simulate biological processes by integrating biological knowledge, experimental data, and computational algorithms. These models can predict molecular interactions, simulate drug mechanisms of action, and assess environmental impacts with high accuracy and efficiency. By leveraging vast datasets and advanced algorithms, in silico modeling offers insights into complex biological systems that are often impractical or ethically challenging to study using traditional methods.
The US Environmental Protection Agency (EPA)8 utilizes in silico models extensively for chemical safety testing and environmental risk assessment. These models predict toxicity levels and environmental impacts, reducing reliance on animal studies while providing robust regulatory data. Similarly, pharmaceutical corporations such as Novo Nordisk employ in silico modeling in drug discovery and development to screen compounds for efficacy and safety profiles before advancing to costly and time-consuming animal studies.
Building on these efforts, the Tox21 Collaboration, involving the National Institutes of Health, EPA, and Food and Drug Administration, exemplifies collaborative efforts to advance in silico modeling. By improving existing models and developing new approaches, Tox21 aims to minimize animal testing while enhancing the reliability and predictive capabilities of toxicity assessments.
In silico models simulate biological processes by integrating biological knowledge, experimental data, and computational algorithms.
These advancements not only accelerate scientific discoveries but also align with ethical principles and regulatory requirements, paving the way for more sustainable and humane practices in biomedical research and environmental safety assessment.
A comparative analysis of animal models versus alternative methods
When considering the accuracy, reliability, scalability, cost-effectiveness, and time efficiency of research methods, both traditional animal models and emerging alternatives offer distinct advantages and challenges. Animal models often struggle to adequately replicate human physiology and disease mechanisms due to interspecies differences. Methods like 3D cell cultures and in silico models can provide more relevant human-specific data.
Reliability is a vital factor influencing experimental outcomes. Animal models can exhibit variability influenced by genetic differences, housing conditions, and stress levels, potentially yielding inconsistent results. Alternatives such as organoids and computational models offer controlled and reproducible experimental conditions, enhancing reliability. Animal studies are also constrained by ethical concerns, space limitations, and resource requirements, whereas in vitro and in silico methods can be scaled up more easily. Computational models, however, can efficiently simulate thousands of scenarios.
Traditional animal research involves substantial expenses for housing, feeding, and veterinary care, whereas alternatives like organoid cultures and computational simulations reduce these costs substantially. Animal studies can be time consuming, taking months or years to complete. High-throughput screening with 3D cell cultures and rapid simulations with computational models offer quicker insights into drug efficacy and toxicity.
However, implementing alternatives presents challenges. Advanced methods require specialized expertise and training for researchers, as well as substantial initial investments in equipment and technology. Validating and gaining regulatory acceptance for new techniques can also require extensive data to demonstrate equivalence or superiority to traditional animal models. Complex interactions may still require validation through animal studies due to current limitations in alternative methodologies.
Lab managers must carefully evaluate these factors and ensure scientific rigor and responsible research practices are upheld. They can promote a future-friendly lab environment by staying informed about new advancements, investing in flexible infrastructure, and supporting collaboration and training on alternative techniques that reduce animal usage. Leading by example, effective communication, and monitoring progress with measurable metrics can facilitate the integration of new alternatives into existing workflows.
References:
1. Thoeny HC, Ross BD. “Predicting and monitoring cancer treatment response with diffusion-weighted MRI.” J Magn Reson Imaging. 2010 Jul;32(1):2-16. doi: 10.1002/jmri.22167.
2. Price AN, et al. “Cardiovascular magnetic resonance imaging in experimental models.” Open Cardiovasc Med J. 2010 Nov 26;4:278-92. doi: 10.2174/1874192401004010278.
3. Wandschneider B, et al. “Levetiracetam reduces abnormal network activations in temporal lobe epilepsy.” Neurology. 2014 Oct 21;83(17):1508-12. doi: 10.1212/WNL.0000000000000910.
4. Walter MA, et al. “Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53-/- Mice.” J Nucl Med. 2010 Aug;51(8). doi: https://doi.org/10.2967/jnumed.109.073585.
5. Hansen, JY, et al. “Mapping neurotransmitter systems to the structural and functional organization of the human neocortex.” Nat Neurosci 25, 1569–1581 (2022). https://doi.org/10.1038/s41593-022-01186-3.
6. Cao, L. “Positron Emission Tomography in Animal Models of Taupathies.” Front Aging Neurosci. 2022 Jan 9;13. doi: https://doi.org/10.3389/fnagi.2021.761913.
7. Lab Manager. “Harnessing 3D Cell Cultures for Drug Discovery and Characterization.” 2023 Dec 15. Accessed from: https://www.labmanager.com/big-picture/cell-culture-advances-and-techniques/harnessing-3d-cell-cultures-for-drug-discovery-and-characterization-31507.
8. United States Environmental Protection Agency. “Predictive Models and Tools for Assessing Chemicals under the Toxic Substances Control Act (TSCA). 2024. Accessed from: https://www.epa.gov/tsca-screening-tools.
